deltatrials
Completed PHASE4 INTERVENTIONAL 3-arm NCT02237417

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

A Randomized, Open Label, Parallel Group, Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism

Sponsor: Otsuka America Pharmaceutical

Conditions Schizophrenia
Interventions IM aripiprazole once monthly No Treatment Standard of Care Oral antipsychotics
Updated 14 times since 2017 Last updated: Feb 26, 2025 Started: Sep 1, 2014 Primary completion: Nov 30, 2018 Completion: Jul 30, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02237417, this PHASE4 trial focuses on Schizophrenia and remains completed. Sponsored by Otsuka America Pharmaceutical, it has been updated 14 times since 2014, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jul 2020 · 14 months · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Dec 2022 · 21 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – present · 15 months · monthly snapshot

Change History

14 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE4

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE4

▶ Show 9 earlier versions

  1. Mar 2021 — Dec 2022 [monthly]

    Completed PHASE4

  2. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE4

  3. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE4

  4. Jul 2020 — Nov 2020 [monthly]

    Completed PHASE4

  5. May 2019 — Jul 2020 [monthly]

    Completed PHASE4

  6. Mar 2019 — May 2019 [monthly]

    Completed PHASE4

    Status: Recruiting → Completed

  7. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE4

  8. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE4

  9. Jan 2017 — Aug 2017 [monthly]

    Recruiting PHASE4

    First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Otsuka America Pharmaceutical
  • University of Utah
Data source: University of Utah

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations